Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exenatide-CTP + Glucagon-CTP
- Development stage
- Phase 1
- Lead developer
- OPKO Health
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Exenatide-CTP + Glucagon-CTP (E1 + G1) is an experimental combination therapy developed by OPKO Health for the treatment of type 2 diabetes mellitus. The therapy utilizes the Carboxy Terminal Peptide (CTP) technology, originally developed by PROLOR Biotech, to extend the half-life of the peptide hormones. E1 is a long-acting GLP-1 receptor agonist (exenatide-CTP), while G1 is a long-acting glucagon receptor agonist (glucagon-CTP). This dual-agonist approach is designed to mimic the metabolic benefits of oxyntomodulin, promoting insulin secretion, suppressing appetite, and increasing energy expenditure to improve glycemic control and facilitate weight loss. The combination was evaluated in Phase 1 clinical trials to determine the safety and optimal ratio of the two components.
- Other names
- Exenatide-CTP and Glucagon-CTP combination
02
Targets
GCGR (Glucagon receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on Exenatide-CTP + Glucagon-CTP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exenatide-CTP + Glucagon-CTP.